Q-omics provides the consensus-scored RGPD4-AS1 profile across patient tissues and cancer cell-line models. RGPD4-AS1 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RGPD4-AS1 is differentially expressed in 2, with the highest sampling consensus in PRAD. Additionally, RGPD4-AS1 RNA expression shows 6,214 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, PRAD, and STAD as cancer lineages where RGPD4-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGPD4-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGPD4-AS1 survival associations across molecular data types. RGPD4-AS1 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGPD4-AS1 RNA expression–survival associations across cancer types. High RGPD4-AS1 expression shows unfavorable associations in MESO, KICH, CHOL and BRCA, but favorable associations in LUAD and CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for RGPD4-AS1 RNA expression.
This table summarizes RGPD4-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for RGPD4-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGPD4-AS1 shows higher tumor expression in PRAD and HNSC. The PRAD box plot shows higher RGPD4-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.007, t-test p = .007).
This table shows molecular features associated with RGPD4-AS1 in patient tissues and cancer cell lines. In patient samples, RGPD4-AS1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
